Randomized Trial: Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
13 Jul, 2018 | 02:33h | UTCCabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Cabozantinib in Hepatocellular Carcinoma – NEJM Resident 360 (free)
Median overall survival was 10.2 months with cabozantinib and 8.0 months with placebo, but the rate of high-grade adverse events in the cabozantinib group was approximately twice that observed in the placebo group.